tbuckley/cabot-search huggingface dataset:
Association of Depressive Symptoms With Incident Cardiovascular Diseases in Middle-Aged and Older Chinese Adults
Authors: Haibin Li, Deqiang Zheng, Zhiwei Li, Zhiyuan Wu, Wei Feng, Xue Cao, Jiaxin Wang, Qi Gao, Xia Li, Wei Wang, Brian J. Hall, Yu-Tao Xiang, Xiuhua Guo
Journal: JAMA Network Open (2019)

The prevalence of depressive symptoms among older adults has become an increasingly important public health priority. Elevated depressive symptoms are well documented among elderly people with cardiovascular disease (CVD), but studies conducted among Chinese adults are scarce.To estimate the association between depressive symptoms and incident CVD among middle-aged and older Chinese adults.The China Health and Retirement Longitudinal Study is an ongoing nationally representative prospective cohort study that was initiated in 2011. This cohort study included 12 417 middle-aged and older Chinese adults without heart disease and stroke at baseline. Statistical analysis was conducted from April 25, 2018, to December 13, 2018.Depressive symptoms were assessed using the validated 10-item of Center for Epidemiologic Studies Depression Scale.Incident CVD (ie, self-reported physician-diagnosed heart disease and stroke combined) was followed-up from June 1, 2011, to June 31, 2015. The Center for Epidemiologic Studies Depression Scale total score ranges from 0 to 30, with a score of 12 or more indicating elevated depressive symptoms.Of the 12 417 participants (mean [SD] age at baseline, 58.40 [9.51] years), 6113 (49.2%) were men. During the 4 years of follow-up, 1088 incident CVD cases were identified. Elevated depressive symptoms were independently associated with an increased CVD risk (adjusted hazard ratio, 1.39; 95% CI, 1.22-1.58) after adjusting for age, sex, residence, marital status, educational level, smoking status, drinking status, systolic blood pressure, and body mass index; history of diabetes, hypertension, dyslipidemia, and chronic kidney disease; and use of hypertension medications, diabetes medications, and lipid-lowering therapy. Of the 10 individual depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale, only 2 symptoms, restless sleep (adjusted hazard ratio, 1.21; 95% CI, 1.06-1.39) and loneliness (adjusted hazard ratio, 1.21; 95% CI, 1.02-1.44), were significantly associated with incident CVD.Elevated depressive symptoms overall and 2 individual symptoms (restless sleep and loneliness) were significantly associated with incident CVD among middle-aged and older Chinese adults.
Endoloop rescue therapy for a duodenal ulcer that re-bled under the clip base after application of an 11/3 traumatic over-the-scope clip
Authors: Carlo Jung, Adrien Sportes, Volker Ellenrieder, Edris Wedi
Journal: Endoscopy (2020)

A 67-year-old patient with melena and symptoms of shock, along with additional clinical symptoms of fatigue and severe anemia (initial hemoglobin level 7.9 g/dL), was transferred to our intensive care unit. The patient had multiple co-morbidities with chronic renal failure, cardiac decompensation, peripheral arterial occlusive disease, and chronic obstructive pulmonary disease. Additionally, he had had a recent arterial embolus and, for this reason, was anticoagulated with heparin. A gastroscopy was performed 3 days after the patient had started anticoagulation therapy, when he presented with clinical signs of gastrointestinal bleeding. A Forrest IIa ulcer was seen in the descending duodenum and, because of the anticoagulation, definitive hemostasis was needed, being achieved following application of an 11/3 traumatic over-the-scope clip (OTSC; Ovesco, Tübingen, Germany). The patient’s clinical course remained stable for the first 9 days. Unfortunately, on postoperative day 9, his physical condition progressively worsened with severe gastrointestinal bleeding, tachycardia, and hypotension, despite endoscopic intervention and transfusion of numerous red blood cell units (n = 8).
Bypass surgery safe for octogenarians
Authors: David Spurgeon
Journal: BMJ (2001)

Cardiac bypass surgery can be as safe for 80 year olds as for those in their 70s—and no more costly, says a study published in the Canadian Medical Association Journal (2001;165:759-64).

The number of octogenarians being referred for cardiac interventions is expected to increase, say the authors, who are with the CADENCE Research Group, Hamilton Health Science, in the department of surgery and the faculty of health sciences at McMaster University in Hamilton, Ontario.

Because of this, the group reviewed data on patients 70 years and older who had undergone bypass surgery at the Hamilton regional cardiac surgical centre between 1 July 1997 and 30 April 2000. A total of 1034 patients were divided into three groups: young septuagenarians (70-74 years), old septuagenarians (75-79), and those 80 and older. Costs were determined in a subset of 773 patients by using a cost casing system developed at the centre.

“There were no significant differences between the three groups in the mean number of grafts per patient (3.0, 3.1, and 3.0 respectively), the rate of postoperative death (3.3% 5.7% and 4.2%), the mean length of stay (11.7, 13.4, and 12.6 days), or the incidence of postoperative myocardial infarction (4.5% 3.4% and 4.2%),” concludes the study. “The total cost of coronary artery bypass grafting per patient did not differ significantly between the three groups.”
Overall Survival (OS) in Metastatic Renal Cell Carcinoma (MRCC) Sequentially Treated with Different Targeted Therapies (TTS): Results from A Large Cohort of Patients
Authors: G. Procopio, E. Verzoni, I. Testa, R. Iacovelli, E. Garanzini, F.G.M. De Braud
Journal: Annals of Oncology (2012)
Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal
Authors: Stephan Busque, John D. Scandling, Robert Lowsky, Judith Shizuru, Kent Jensen, Jeffrey Waters, Hsin-Hsu Wu, Kevin Sheehan, Asha Shori, Okmi Choi, Thomas Pham, Marcelo A. Fernandez Vina, Richard Hoppe, John Tamaresis, Philip Lavori, Edgar G. Engleman, Everett Meyer, Samuel Strober
Journal: Science Translational Medicine (2020)

Preclinical studies have shown that persistent mixed chimerism is linked to acceptance of organ allografts without immunosuppressive (IS) drugs. Mixed chimerism refers to continued mixing of donor and recipient hematopoietic cells in recipient tissues after transplantation of donor cells. To determine whether persistent mixed chimerism and tolerance can be established in patients undergoing living donor kidney transplantation, we infused allograft recipients with donor T cells and hematopoietic progenitors after posttransplant lymphoid irradiation. In 24 of 29 fully human leukocyte antigen (HLA)-matched patients who had persistent mixed chimerism for at least 6 months, complete IS drug withdrawal was achieved without subsequent evidence of rejection for at least 2 years. In 10 of 22 HLA haplotype-matched patients with persistent mixed chimerism for at least 12 months, reduction of IS drugs to tacrolimus monotherapy was achieved. Withdrawal of tacrolimus during the second year resulted in loss of detectable chimerism and subsequent rejection episodes, unless tacrolimus therapy was reinstituted. Posttransplant immune reconstitution of naïve B cells and B cell precursors was more rapid than the reconstitution of naïve T cells and thymic T cell precursors. Robust chimerism was observed only among naïve T and B cells but not among memory T cells. No evidence of rejection was observed in all surveillance graft biopsies obtained from mixed chimeric patients withdrawn from IS drugs, and none developed graft-versus-host disease. In conclusion, persistent mixed chimerism established in fully HLA- or haplotype-matched patients allowed for complete or partial IS drug withdrawal without rejection.
Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials
Authors: Linda Stein Gold, James Q. Del Rosso, Leon Kircik, Neal D. Bhatia, Deirdre Hooper, Walter K. Nahm, Iain Stuart
Journal: Journal of the American Academy of Dermatology (2020)

Efficacious topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery.To determine the efficacy, safety, and tolerability of 12 weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea.Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea.Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11: -17.57 vs -15.65; P = .0031; FX2016-12: -18.54 vs -14.88; P < .0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11: 52.1% vs 43.0%; P = .0273; FX2016-12: 49.1% vs 39.0%; P = .0077). No serious treatment-related treatment-emergent adverse events occurred.The generalizability of these data from a controlled clinical trial should be examined in a real-world setting.FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile.
Abstract 284: Cerebral Oximetry During Resuscitation: Course and Outcome
Authors: Jenny Shin, Jennifer E Blackwood, Rob G Walker, Fred W Chapman, Joe Crackel, Thomas Rea
Journal: Circulation (2019)

Background: Anoxic brain injury is a common cause of death following out-of-hospital cardiac arrest (OHCA). Cerebral oximetry provides a real-time tool to brain ischemia. Little is known about the course of cerebral oximetry and its relationship to outcome following OHCA. Methods: We conducted a pilot cohort study during OHCA to evaluate the course and prognosis related to cerebral oximetry in a single US EMS agency. Cerebral oximetry was applied by first responders at the outset of EMS resuscitation using the Nonin SenSmart Model X-100 Universal Oximetry System. EMS providers were blinded to oximeter information. The oximeter recording was linked to the defibrillator recording and the OHCA clinical registry, which includes the outcomes of return of spontaneous circulation (ROSC) and survival to hospital discharge with good function as determined by Cerebral Performance Category (CPC) of 1 or 2. We evaluated the variability of cerebral oximetry over time and the relationship between oximetry and outcome according to ROSC and survival status. Results: Of the 100 eligible OHCA events, 81 had complete oximeter and defibrillator information. Average age was 62, 43% were female, 14% presented with ventricular fibrillation, 49% (n=40) achieved ROSC, and 16% (n=13) survived (all with CPC of 1 or 2). Average initial cerebral oxygen saturation was 46% (SD 15) among all cases and among those requiring resuscitation &gt;10 minutes. Among those with ongoing resuscitation, mean oximetry was 49% at 5 minutes and 51% at 10 minutes. The average change in oximetry during resuscitation was 8% with 59% demonstrating an increase in oximetry, 32% a decrease, and 9% no change. Brain oximetry increased 10% following ROSC. Initial cerebral oximetry was 53% (SD 18) among survivors versus 44% (SD 15) among non-survivors (p=0.1). When stratified by groups defined by ROSC and survival, initial brain oximetry was 43% among those without ROSC, 46% among those who achieved ROSC but did not survive, and 53% among those who survived (p=0.1 test for trend). Conclusion: Cerebral oximetry can be deployed by first responders in OHCA. Cerebral oximetry exhibits some variability during the course of resuscitation and increases with ROSC. Whether cerebral oximetry can be used to guide care is uncertain.
Correction: Human IgA bind a diverse array of commensal bacteria
Authors: Delphine Sterlin, Jehane Fadlallah, Olivia Adams, Claire Fieschi, Christophe Parizot, Karim Dorgham, Asok Rajkumar, Gaëlle Autaa, Hela El-Kafsi, Jean-Luc Charuel, Catherine Juste, Friederike Jönsson, Thomas Candela, Hedda Wardemann, Alexandra Aubry, Carmen Capito, Hélène Brisson, Christophe Tresallet, Richard D. Cummings, Martin Larsen, Hans Yssel, Stephan von Gunten, Guy Gorochov
Journal: The Journal of Experimental Medicine (2020)

the x-and y-axes labels in Fig. 1 E were missing as a result of a conversion error.
Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality
Authors: Yoriko Heianza, Wenjie Ma, Xiang Li, Yin Cao, Andrew T. Chan, Eric B. Rimm, Frank B. Hu, Kathryn M. Rexrode, JoAnn E. Manson, Lu Qi
Journal: Circulation Research (2019)

Rationale: The overuse of antibiotics has been an important clinical issue, and antibiotic exposure is linked to alterations in gut microbiota, which has been related to risks of various chronic diseases such as cardiovascular disease and cancer. Also, duration of antibiotic exposure may be a risk factor of premature death. Objective: We investigated associations of life-stage and duration of antibiotic use during adulthood with risks of all-cause and cause-specific mortality. Methods and Results: This prospective cohort study included 37 516 women aged ≥60 years who were free of cardiovascular disease or cancer from the Nurses' Health Study. Participants reported a total amount of time they used antibiotics (none, <15 days, 15 days to <2 months, or ≥2 months) in the middle- (age, 40-59) and late adulthood (age, 60 or older). We estimated hazard ratios for all-cause mortality and deaths from cardiovascular disease or cancer over 10 years according to duration of antibiotic use. During 355 918 person-years of follow-up, we documented 4536 deaths from any cause (including 728 cardiovascular deaths and 1206 cancer deaths). As compared with women who did not use antibiotics, those who used them for ≥2 months in late adulthood had increased risks of all-cause mortality (hazard ratio, 1.16 [95% CI, 1.01-1.33]) and cardiovascular mortality (hazard ratio, 1.49 [95% CI, 1.04-2.13]), but not cancer mortality (hazard ratio, 0.85 [95% CI, 0.65-1.12]) after adjustment for chronic metabolic diseases, antibiotic use during middle adulthood, indication for use, demographic factors, and lifestyle/dietary factors. The association was more evident among women who also used antibiotics in middle-adulthood than among those who did not use during this life-stage. Conclusions: Long-term use of antibiotics in late adulthood may be a risk factor for all-cause and cardiovascular mortality. The unfavorable effect of antibiotic exposure for subsequent risks of deaths due to chronic diseases needs to be considered.
A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides
Authors: Anna Wolska, Larry Lo, Denis O. Sviridov, Mohsen Pourmousa, Milton Pryor, Soumitra S. Ghosh, Rahul Kakkar, Michael Davidson, Sierra Wilson, Richard W. Pastor, Ira J. Goldberg, Debapriya Basu, Steven K. Drake, Antony Cougnoux, Ming Jing Wu, Saskia B. Neher, Lita A. Freeman, Jingrong Tang, Marcelo Amar, Matt Devalaraja, Alan T. Remaley
Journal: Science Translational Medicine (2020)

An apolipoprotein C-II peptide mimetic for the treatment of hypertriglyceridemia activates lipoprotein lipase and blocks apolipoprotein C-III.
125P Community Therapy by Early Breast Cancer Detection and its Prevention by Lifestyle Modification
Authors: S. Koner, J. Basak, A. Chakraborty, D. Bhattacharya Majumder, S. Dasgupta, P. Das, N. Pal, S. Sen, S. Mukhopadhyay, A. Mukhopadhyay
Journal: Annals of Oncology (2012)
Abstract 436: Ventilation Rate Impact on End-Tidal Carbon Dioxide Levels During Manual Cardiopulmonary Resuscitation
Authors: Jesus M Ruiz, Jose J Gutierrez, Sofia Ruiz de Gauna, Mikel Leturiondo, Luis A Leturiondo, Carlos Corcuera, James K Russell, Mohamud R DAYA
Journal: Circulation (2019)

Introduction: End-tidal carbon dioxide (ETCO2) levels during cardiopulmonary resuscitation (CPR) depend primarily on the blood flow generated by chest compressions, on the ventilation rate and on the metabolic activity of the patient tissues. A better characterization of the influence of each factor is warranted. Objective: To assess the quantitative relation between ETCO2 and ventilation rate from retrospective analysis of adult out-of-hospital resuscitations. Methods: Monitor recordings of 163 adult out-of-hospital cardiac arrest cases treated by Tualatin Valley Fire &amp; Rescue (Tigard, OR) from 2012 through 2017. Recordings contained concurrent capnogram, ECG, transthoracic impedance (TI) and compression depth. Episodes were manually inspected to identify pairs of segments with different ventilation rates ( vr 1, vr 2) and meeting the following criteria: 1) Reliable capnogram to annotate the ETCO2 value of each segment ( ET 1, ET 2). 2) A maximum of 2 min separation between segments so that similar metabolic activity could be assumed. 3) Absence of circulation, by inspecting the ECG and the TI signal. 4) Compression depth and rate variation between segments &lt; 4 mm and 8 compressions per minute, respectively. We applied curve fitting to the data with a custom equation (see figure) and non-linear least squares as fit option. Results: Forty pairs of segments were included. The figure shows the measurements and the resulting fitting curve normalized to vr 1 = 10 ventilations per minute (vpm). Factor K was 0.93, and the coefficient of determination R 2 was 0.90. Thus, for instance, the ETCO2 at 5 vpm would be 1.64 times the ETCO2 at 10 vpm. Similarly, the ETCO2 at 15 vpm would be 0.80 times the ETCO2 at 10 vpm. Conclusions: The obtained curve may help to eliminate the influence of ventilation rate on ETCO2 during cardiopulmonary resuscitation. This finding is a step forward to a better understanding of ETCO2 variation during the course of resuscitation.
Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
Authors: Javier Jimenez, Eran C. Gwillim, Cory Kosche, Anna Figueiredo, Corrine Rauck, Stephanie M. Rangel, Jennifer Choi, Dennis P. West, Beatrice Nardone, Mario E. Lacouture
Journal: Journal of the American Academy of Dermatology (2020)
Bisphosphonates in Bone Metastatic Patients: Experience of Medical Oncology, University of L'Aquila Over 17 Years
Authors: E. Ricevuto, A. Irelli, K. Cannita, G. Bruera, P. Lanfiuti Baldi, V. Cocciolone, E. Palluzzi, L. Rinaldi, A. Teti, C. Ficorella
Journal: Annals of Oncology (2012)
Annals Graphic Medicine - Dr. Mom: Syncope
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2020)

Web Exclusives4 February 2020Annals Graphic Medicine - Dr. Mom: SyncopeFREEGrace E. Farris, MDGrace E. Farris, MDMount Sinai School of Medicine, New York, New York (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0091 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Mount Sinai School of Medicine, New York, New York (G.E.F.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0042.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Icahn School of Medicine at Mount Sinai and chief of hospital medicine at Mount Sinai West hospital in New York, New York. You can view her work at her Web site: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine at Annals.org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 February 2020Volume 172, Issue 3Page: W1-W2KeywordsConflicts of interestDisclosureHospital medicineHospitalistsSyncope ePublished: 4 February 2020 Issue Published: 4 February 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28).
Authors: Ludovic Bourre, Delphine Nicolle, Marie-Emmanuelle Legrier, Vanessa Yvonnet, Julie Charpentier, Marie-France Poupon, Patricia Vrignaud, Christine Geffriaud-Ricouard, Stephane Oudard, Jean-Gabriel Judde
Journal: Journal of Clinical Oncology (2012)

e15161 Background: Docetaxel was the first cytotoxic treatment demonstrating a survival benefit in metastatic castration-resistant prostate cancer (mCRPC) patients. Recently, cabazitaxel (a novel taxane) and abiraterone acetate (specific inhibitor of CYP17) have demonstrated a significant survival benefit in mCRPC patients progressing after receiving a docetaxel – containing regimen. Here we compare the antitumor efficacy of docetaxel, cabazitaxel and abiraterone acetate in the HID28 hormone-refractory human prostate carcinoma xenograft. Methods: HID28 tumor bearing nude mice received 20 mg/kg of docetaxel (IP, q3wk x 2), cabazitaxel at 15 and 20 mg/kg (IP, q3wk x 2) and abiraterone acetate at 50 mg/kg (PO, qdx21). Median tumor growth inhibition (T/C%) was evaluated as well as time course androgen receptor expression (4, 8 and 24h post dosing) by western blot analysis. Results: Docetaxel (20 mg/kg) inhibited tumor growth with a T/C%= 16.7% at D35, 2 partial (PR) and 1 complete (CR) tumor regressions, and with relapse of all tumors (6/6) observed at D42. Cabazitaxel demonstrated dose-dependent efficacy at D35 with T/C%= 10.8% and 1.4% for 15 and 20 mg/kg doses respectively. At a cabazitaxel dose of 15 mg/kg, 4/10 PR and 3/10 CR were observed, whereas 4/10 PR and 6/10 CR were observed at 20 mg/kg. At D42, 6/6 tumor relapses were observed at 15 mg/kg; whereas, only 3/6 relapses were observed at 20 mg/kg. No anti-tumor activity was demonstrated with abiraterone acetate as well as no significant decreases in testosterone levels compared to the vehicle group. Tolerability was good for all treatment groups, with a transitory maximum mean body weight loss of 12%, 6 days after treatments. Androgen receptor western blot expression analysis after 4, 8 and 24h post dosing demonstrated no significant difference between groups and over time. Conclusions: Cabazitaxel and docetaxel showed similar tolerability at equivalent dose levels. Cabazitaxel demonstrated superior antitumor efficacy over docetaxel at equivalent dosing in the HID28 hormone-refractory tumor model. These results support the clinical development of cabazitaxel in first line treatment of mCRPC patients.
First-Line Treatment with Folfirinox in Advanced, Inoperable Pancreatic Cancer (APDAC) Patients (PTS): Supportive Measures Optimization for a Safe Administration in Routine Clinical Practice
Authors: V. Vaccaro, E. Bria, I. Sperduti, F. Massari, M.S. Pino, E. Lucchini, A. Gelibter, F. Cognetti, G. Tortora, M. Milella
Journal: Annals of Oncology (2012)
A woman with acute dyspnoea
Authors: Qiaoling Zhou, Madhu Potluri
Journal: BMJ (2020)

A 60 year old woman with end stage renal disease presented with acute dyspnoea over three days.

Her end stage renal disease was secondary to diabetic nephropathy and she had been on daily automated peritoneal dialysis for more than 24 months. She had no other medical history. In the three weeks before her admission, she reported increasing leg oedema and reducing fluid removal from the automated peritoneal dialysis. She noticed that her symptoms of breathlessness worsened whenever she had the dialysates infused.

Examination revealed markedly reduced breath sounds and dull percussion over the left hemithorax.

Chest radiography (fig 1) showed a …